RegenXBio’s RGX-202: Promising DMD Therapy with Best-in-Class Potential and Strategic BLA Plans
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
GlobalData on MSN20h
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy
Regenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...
Brokerages Set REGENXBIO Inc. (NASDAQ:RGNX) PT at $35.64
REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst ...
precisionmedicineonline22h
Regenxbio Treats First Patient in Pivotal Stage of Duchenne Muscular Dystrophy Gene Therapy Trial
The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.